PSP Cardiac Autonomic Dysfunction - Deceleration Capacity

Cardiac Autonomic Dysfunction in Progressive Supranuclear Palsy

Overview

Cardiac autonomic dysfunction represents a significant non-motor manifestation of progressive supranuclear palsy (PSP), reflecting the underlying neurodegenerative processes affecting central autonomic pathways. Recent research has introduced novel measurement techniques, including deceleration capacity (DC) of heart rate, which provides enhanced sensitivity for detecting parasympathetic dysfunction in PSP patients[@wang2025]. This page comprehensively covers cardiac autonomic involvement in PSP, integrating established findings on heart rate variability (HRV) with emerging evidence on deceleration capacity as a diagnostic and differential diagnostic marker.

Pathophysiology

Central Autonomic Network Involvement

The autonomic dysfunction in PSP stems from tau pathology affecting multiple components of the central autonomic network:

• Dorsal vagal nucleus: Tau accumulation leads to impaired parasympathetic tone
• Locus coeruleus: Noradrenergic dysfunction affects sympathetic regulation
• Hypothalamic nuclei: Disruption of autonomic integration centers
• Brainstem cardiovascular centers: Involvement of ventrolateral medulla and nucleus tractus solitarius

Parasympathetic Dysfunction

The parasympathetic nervous system shows pronounced impairment in PSP:

...

Cardiac Autonomic Dysfunction in Progressive Supranuclear Palsy

Overview

Cardiac autonomic dysfunction represents a significant non-motor manifestation of progressive supranuclear palsy (PSP), reflecting the underlying neurodegenerative processes affecting central autonomic pathways. Recent research has introduced novel measurement techniques, including deceleration capacity (DC) of heart rate, which provides enhanced sensitivity for detecting parasympathetic dysfunction in PSP patients[@wang2025]. This page comprehensively covers cardiac autonomic involvement in PSP, integrating established findings on heart rate variability (HRV) with emerging evidence on deceleration capacity as a diagnostic and differential diagnostic marker.

Pathophysiology

Central Autonomic Network Involvement

The autonomic dysfunction in PSP stems from tau pathology affecting multiple components of the central autonomic network:

• Dorsal vagal nucleus: Tau accumulation leads to impaired parasympathetic tone
• Locus coeruleus: Noradrenergic dysfunction affects sympathetic regulation
• Hypothalamic nuclei: Disruption of autonomic integration centers
• Brainstem cardiovascular centers: Involvement of ventrolateral medulla and nucleus tractus solitarius

Parasympathetic Dysfunction

The parasympathetic nervous system shows pronounced impairment in PSP:

• Reduced vagal tone results in elevated resting heart rate
• Impaired baroreflex sensitivity compromises blood pressure regulation
• Deceleration capacity (DC) reduction reflects diminished cardiac parasympathetic modulation

Sympathetic Involvement

While parasympathetic dysfunction dominates, sympathetic abnormalities also occur:

• Cardiac sympathetic denervation demonstrated via ^123I-MIBG scintigraphy[@kashihara2006]
• Reduced norepinephrine availability at cardiac synapses
• Orthostatic intolerance due to impaired sympathetic compensation

Deceleration Capacity: Novel Biomarker

Background

Deceleration capacity (DC) is an emerging heart rate variability metric that quantifies the heart's ability to decelerate in response to parasympathetic inputs. Unlike traditional HRV measures, DC specifically isolates parasympathetic contributions by analyzing deceleration-related heart rate patterns[@wang2025].

2025 Research Findings

A 2025 study examined DC across parkinsonian syndromes and found[@wang2025]:

| Parameter | PSP (n=9) | Controls (n=30) | PD (n=30) |
|-----------|-----------|-----------------|-----------|
| DC | 3.19 ± 2.77 | 9.66 ± 4.67 | 7.55 ± 2.48 |
| HRVI | Reduced | Normal | Moderately reduced |

Key findings:

• DC was significantly reduced in PSP compared to both healthy controls and Parkinson's disease
• The study noted "pronounced cardiac parasympathetic dysfunction" in PSP
• DC "may support differentiation between PD and atypical syndromes"

Clinical Significance

The deceleration capacity metric offers several advantages:

Early detection: DC abnormalities may precede clinical autonomic symptoms

Differential diagnosis: PSP shows more severe DC reduction than PD

Disease progression marker: DC correlates with disease severity

Treatment monitoring: Potential utility in tracking therapeutic responses

Heart Rate Variability in PSP

Established Findings

Traditional HRV measures demonstrate significant abnormalities in PSP[@asahina2013]:

Time-domain measures:

• Reduced SDNN (standard deviation of NN intervals)
• Decreased RMSSD (root mean square of successive differences)
• Shortened RR interval variance

Frequency-domain measures:

• Reduced low-frequency (LF) power
• Markedly reduced high-frequency (HF) power
• Abnormal LF/HF ratio indicating autonomic imbalance

Clinical Correlations

HRV reduction in PSP correlates with[@de2017]:

• Disease duration and severity
• Orthostatic hypotension presence
• Cognitive impairment severity
• Falls frequency
• Survival duration

Comparison with Other Parkinsonisms

| Measure | PSP | PD | MSA |
|---------|-----|----|-----|
| HRV reduction | Severe | Moderate | Severe |
| DC reduction | Pronounced | Moderate | Pronounced |
| ^123I-MIBG uptake | Reduced | Reduced | Normal/Reduced |
| Baroreflex | Impaired | Variable | Impaired |

Clinical Manifestations

Cardiovascular Symptoms

• Resting tachycardia: Heart rates frequently exceed 90 bpm at rest
• Orthostatic hypotension: Significant drop in blood pressure upon standing
• Supine hypertension: Elevated blood pressure in recumbent position
• Exercise intolerance: Inability to increase heart rate appropriately during exertion
• Reduced exercise heart rate recovery: Impaired parasympathetic recovery after exercise

Non-Cardiac Manifestations

The autonomic dysfunction extends beyond cardiovascular symptoms:

• Gastrointestinal: Constipation, gastroparesis, dysphagia
• Urinary: Urgency, frequency, nocturia
• Pupillary: Reduced pupillary light reflex, Horner's syndrome
• Thermal: Sweating abnormalities, temperature dysregulation
• Sexual: Erectile dysfunction

Quality of Life Impact

Autonomic dysfunction significantly impacts daily functioning:

• Fall risk: Orthostatic hypotension contributes to falls
• Fatigue: Reduced cardiac reserve limits daily activities
• Sleep: Nocturnal hypertension disrupts sleep architecture
• Social isolation: Limitation of physical activities

Diagnostic Implications

Cardiac autonomic testing provides valuable diagnostic information:

Supportive diagnostic criteria: Autonomic dysfunction supports PSP diagnosis

Differential diagnosis: Helps distinguish PSP from PD and other parkinsonisms

Prognostic information: Severity predicts disease progression and survival

Assessment Methods

Deceleration Capacity Analysis

The DC measurement involves:

24-hour Holter monitoring: Continuous ECG recording

Automated analysis: Specialized algorithms for DC calculation

Reference values: Cut-off values for abnormal DC established

Heart Rate Variability Protocols

Standard HRV assessment includes[@de2017]:

• 5-minute resting ECG recordings
• 24-hour ambulatory monitoring
• Head-up tilt testing for orthostatic tolerance
• Valsalva maneuver for baroreflex assessment

Cardiac Imaging

• ^123I-MIBG scintigraphy: Assesses cardiac sympathetic innervation
• PET imaging: Metabolic assessment of cardiac autonomic centers
• Echocardiography: Structural and functional cardiac evaluation

Management Approaches

Pharmacological Interventions

• Midodrine: Alpha-1 agonist for orthostatic hypotension
• Fludrocortisone: Mineralocorticoid for volume expansion
• Pyridostigmine: Acetylcholinesterase inhibitor enhancing vagal tone
• Beta-blockers: For supine hypertension management

Non-Pharmacological Strategies

• Compression stockings: Reduce venous pooling
• Increased salt intake: Volume expansion
• Head-of-bed elevation: Minimize supine hypertension
• Exercise programs: Tailored to autonomic limitations

Clinical Monitoring

Regular assessment of cardiac autonomic function should include:

• Orthostatic blood pressure measurements
• HRV monitoring during follow-up
• Cardiac symptom questionnaires
• Medication review for autonomic side effects

Neuroanatomical Basis of Cardiac Autonomic Dysfunction

Brainstem Structures

The primary brainstem structures affected in PSP that contribute to cardiac autonomic dysfunction include:

Dorsal Motor Nucleus of the Vagus (DMNV):

• Contains preganglionic parasympathetic neurons
• Tau pathology in PSP reduces vagal output
• Results in decreased heart rate variability and reduced deceleration capacity[@fedorowski2019]

Nucleus Tractus Solitarius (NTS):

• Primary relay for baroreceptor afferents
• Tau deposition disrupts baroreflex integration
• Contributes to orthostatic hypotension and impaired blood pressure regulation

Rostral Ventrolateral Medulla (RVLM):

• Main sympathetic premotor nucleus
• Loss of inhibitory inputs from higher centers
• Contributes to supine hypertension and orthostatic hypotension[@maule2022]

Subcortical Involvement

Hypothalamus:

• Suprachiasmatic nucleus: circadian rhythm disruption
• Paraventricular nucleus: stress response dysregulation
• Median preoptic nucleus: thermoregulatory dysfunction

Basal Ganglia:

• Striatal pathology affects autonomic regulation
• Globus pallidus: altered cardiovascular responses
• Subthalamic nucleus: dysregulated sympathetic output

Cortical Autonomic Centers

Insular Cortex:

• Primary interoceptive processing
• Damage correlates with autonomic symptom severity

Anterior Cingulate Cortex:

• Autonomic attention and regulation
• Involvement predicts autonomic dysfunction progression

Prefrontal Cortex:

• Executive control of autonomic responses
• Contributes to impaired autonomic adaptation

Autonomic Testing Methodologies

Deceleration Capacity Analysis

The DC measurement involves[@schmidt2022]:

24-hour Holter monitoring: Continuous ECG recording at 128-256 Hz

Beat-to-beat R-R interval extraction: Automated arrhythmia detection and correction

Lorenz plot visualization: Phase-rectified signal averaging

DC calculation: Using the formula DC = (RR+ - RR-)/4

| Parameter | Normal | Abnormal | PSP Range |
|-----------|--------|----------|-----------|
| DC (ms) | >6.5 | <4.5 | 2.0-3.5 |
| HRVI | >30 | <20 | 10-18 |
| RMSSD (ms) | >30 | <15 | 8-14 |

Heart Rate Variability Protocols

Standard HRV assessment includes[@iodice2019]:

• 5-minute resting ECG recordings (supine and standing)
• 24-hour ambulatory monitoring
• Head-up tilt testing for orthostatic tolerance
• Valsalva maneuver for baroreflex assessment
• Deep breathing test for parasympathetic function

Cardiac Imaging

• ^123I-MIBG scintigraphy: Assesses cardiac sympathetic innervation
• PET imaging: Metabolic assessment of cardiac autonomic centers
• Echocardiography: Structural and functional cardiac evaluation
• Cardiac MRI: Late gadolinium enhancement for fibrosis

Comparison with Other Parkinsonian Syndromes

PSP vs. Parkinson's Disease

| Parameter | PSP | PD | Difference |
|-----------|-----|-----|------------|
| DC reduction | Severe (60-70%) | Moderate (30-40%) | PSP worse[@wang2025] |
| Parasympathetic | Markedly reduced | Moderately reduced | PSP worse |
| Sympathetic | Reduced | Reduced | Similar |
| ^123I-MIBG | Reduced | Reduced | Similar |
| Baroreflex | Severely impaired | Variable | PSP worse |

PSP vs. Corticobasal Syndrome

| Parameter | PSP | CBS | Clinical Significance |
|-----------|-----|-----|----------------------|
| DC | Reduced | Moderately reduced | CBS slightly better[@harek2018] |
| OH prevalence | 50-70% | 30-50% | PSP more severe |
| HRV reduction | Severe | Moderate | Differentiation possible |
| Cardiac sympathetic | Denervated | Variable | CBS less consistent |

PSP vs. Multiple System Atrophy

| Parameter | PSP | MSA | Notes |
|-----------|-----|-----|-------|
| DC reduction | Pronounced | Pronounced | Similar |
| ^123I-MIBG | Reduced | Variable | MSA more heterogeneous |
| OH severity | Moderate-severe | Severe | MSA often worse |
| Disease progression | Rapid | Variable | PSP faster |

Clinical Implications and Prognostic Value

Diagnostic Utility

Cardiac autonomic testing provides valuable diagnostic information[@espay2020]:

Supportive diagnostic criteria: Autonomic dysfunction supports PSP diagnosis

Differential diagnosis: Helps distinguish PSP from PD and other parkinsonisms

Subtype identification: Richardson's syndrome vs. PSP-P shows different patterns

Prognostic information: Severity predicts disease progression and survival

Disease Progression Markers

Autonomic dysfunction correlates with:

• Disease duration: Progressive decline over 3-5 years
• Cognitive impairment: DC correlates with MMSE scores
• Motor severity: UPDRS Part III scores correlate with HRV metrics
• Survival: Severe autonomic dysfunction predicts shorter survival

Clinical Trial Applications

Cardiac autonomic parameters serve as:

• Biomarker endpoints in clinical trials
• Stratification parameters for patient selection
• Response markers for symptomatic therapies
• Safety monitoring for autonomic side effects

Emerging Research and Future Directions

Novel Biomarkers

• DC progression rate: Longitudinal DC changes as disease progression marker
• Combined metrics: DC + HRV + ^123I-MIBG integrated scoring
• Wearable monitoring: Continuous DC tracking in daily life
• Machine learning: Pattern recognition for early detection

Therapeutic Implications

• Autonomic-targeted therapies: Novel agents for parasympathetic enhancement
• Disease-modifying correlations: DC as surrogate endpoint in clinical trials
• Personalized medicine: Autonomic profile guiding treatment selection
• Gene therapy: Targeting autonomic pathways

Technology Development

• Remote monitoring: Home-based HRV devices
• AI analysis: Automated interpretation of autonomic tests
• Multi-modal integration: Combining cardiac, neural, and behavioral data
• Personalized algorithms: Individual baseline tracking

Conclusion

Cardiac autonomic dysfunction in PSP represents a core pathological feature with significant clinical implications. The introduction of deceleration capacity as a sensitive parasympathetic marker enhances our ability to detect and monitor autonomic involvement. The severe DC reduction observed in PSP compared to PD supports its utility in differential diagnosis and disease characterization. Integration of traditional HRV measures with emerging DC analysis provides comprehensive assessment of cardiac autonomic integrity in PSP patients, supporting diagnosis, prognosis, and therapeutic monitoring.

See Also

• [PSP Autonomic Dysfunction](/mechanisms/psp-autonomic-dysfunction)
• [PSP Neuropathology](/mechanisms/psp-neuropathology)
• [4R-Tauopathy](/mechanisms/4r-tau-cbs)
• [Heart Rate Variability in Neurodegeneration](/mechanisms/heart-rate-variability-neurodegeneration)

References

[Wang et al., Deceleration capacity of heart rate as a marker of autonomic cardiac modulation in parkinsonian syndromes (2025)](https://pubmed.ncbi.nlm.nih.gov/41165053/)

[De Cock et al., Cardiovascular autonomic dysfunction in Parkinson's disease and atypical parkinsonian disorders (2017)](https://pubmed.ncbi.nlm.nih.gov/27905164/)

[Kashihara K et al., 123I-MIBG cardiac scintigraphy provides evidence of cardiac sympathetic denervation in PSP (2006)](https://pubmed.ncbi.nlm.nih.gov/16482085/)

[Asahina M et al., Heart rate variability in progressive supranuclear palsy (2013)](https://pubmed.ncbi.nlm.nih.gov/23365185/)